arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PROCEPT BioRobotics Corp

PRCT
$20.25 ▼ -1.42 (-6.55%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

PROCEPT BioRobotics Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.2B
Dividend Yield —
Revenue Growth 19.3% ↘
Op. Margin -29.0% ↗
ROIC -7.0% ↗
FCF / Share $-0.39 ↗
Trailing P/E —
Price / Book 3.4x
FCF Yield —
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$94.50M
↑ +19.3% —
Net Income Profit after all expenses
$-31.64M
↓ -27.9% —
Operating Margin Operating profit as % of sales
-29.0%
↑ +26.1% 7th
FCF / Share Free cash flow per share
$-0.39
↓ -20.9% —
Long-Term Debt Long-term obligations
$51.72M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↓
25
Financial Health ↓
50
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters